Latest Articles
-
Merck Stock Remains Significantly Undervalued At $77
Merck (NYSE: MRK) looks very attractive at current levels of $77, as it is up only 17% from the levels it was at on March 23, 2020, when broader markets made a bottom due to the spread of Covid-19. This marks a significant underperformance compar...
-
Merck Q4 Earnings Preview: Keytruda And Gardasil In Focus
Merck (NYSE: MRK) is scheduled to report its Q4 2020 results on Thursday, February 4. We expect the company to likely post revenue slightly below and earnings in-line with the consensus estimates, partly due to lower expected sales of vaccines, s...
-
What’s Happening With Merck Stock?
[Updated 12/2/2020] Merck Update Merck (NYSE: MRK) recently announced that it has sold its equity investment in Moderna. Merck has benefited from a whopping 7x surge in Moderna stock this year, given its Covid-19 vaccine development. Though, de...
-
Forecast of the Day: Merck’s Oncology Drugs Sales
The FDA has approved Merck’s (NYSE: MRK) Keytruda (pembrolizumab), combined with chemo, for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1. This ad...
-
Merck Stock Poised For 25% Gains
Merck’s stock (NYSE: MRK) lost more than 28% – dropping from $92 at the beginning of the year to $66 in late March – then jumped 21% to around $80 now. That means it has partially recovered to the levels where it started the year. That ...
-
Should You Buy Merck Stock At $85?
After a 28% rise since the March 23 lows of this year, at the current price of around $85 per share we believe Merck’s stock (NYSE: MRK) looks attractive and it has more room for growth. MRK stock has moved from $66 to $85 off the recent bottom c...
-
Consider Buying Merck Over Johnson & Johnson’s Stock
Johnson & Johnson’s stock (NYSE:JNJ) has gained 38% since the March 23 lows of this year, while Merck’s stock (NYSE:MRK) has slightly underperformed and gained 30% of its value. The lockdown in various parts of the world has had a nega...
-
Eli Lilly Stock Is Trending But Is Merck Better?
Merck’s stock (NYSE:MRK) has declined by close to 10% since early February after the WHO declared the coronavirus a global health emergency, while Eli Lilly stock (NYSE:LLY) has fared much better and gained 15%. The lockdown in various par...
-
Merck Over Roche For 25% Gains?
Two pharmaceutical giants – Merck (NYSE:MRK) and Roche (OTCMKTS:RHHBY) – have seen their stock price grow over 20% since March 23 lows, significantly underperforming the broader markets, which rallied over 40% through June 5 from the ...
-
Merck’s Stock Headed To $100?
Merck’s stock (NYSE:MRK) has underperformed the broader markets as well as some of its peers over the last few weeks. While Merck’s stock grew 20% since the recent lows of March 23, the S&P 500 gained 26%. Looking at other pharmac...
-
After Allergan Acquisition Is AbbVie A Better Buy Compared To Merck?
The pharmaceutical companies have not been immune to the current coronavirus crisis, although they have fared much better than the broader markets. While Merck’s (NYSE:MRK) stock has declined 9% since early February, after the WHO declared ...
-
Despite Outperforming The Broader Markets, Merck Appears To Be Oversold At $80
Merck (NYSE:MRK) stock declined 10% from $90 levels in the beginning of this year to $80 levels as of April 22, compared to a 13% decline for the broader S&P 500. While Merck’s stock has marginally outperformed the broader markets, we believe...
-
Can Merck’s Keytruda Be Worth $200 Billion?
Keytruda is to Merck (NYSE:MRK), the way iPhone is to Apple. From nothing, it garnered >$11 billion in sales over the last 5 years, and it is now a leading oncology drug. In this note, Can Merck’s Keytruda Be Worth $200 Billion By 2025 ?, ...
-
35% Upside For Merck’s Stock?
Merck (NYSE:MRK) could see a 35% upside from the current levels, based on our price estimate of $96, which is based on expected 2020 earnings of $5.85 on an adjusted basis, and a price to earnings multiple of 16.4x. Merck’s stock has seen ...
-
How Merck Gets To $51 Billion: Oncology or Vaccines?
Merck (NYSE:MRK) revenue grew from $39.8 billion in 2016 to $46.8 billion in 2019, and it is estimated to top $51.5 billion in 2020, primarily driven by its oncology drug, Keytruda, according to our estimates. The company’s oncology drugs will a...
